This newly developed ADPKD model will promote translational medicine from in vivo preclinical trials to ADPKD therapies and will also provide a platform for identifying new molecular targets for treating ADPKD based on the newly defined mTORC1–CDK1/cyclin axis. Here, CDK1 is linked to autosomal dominant polycystic kidney disease.